drugset / Trial / NCT07528235
An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH
NaSingle-groupOpen-labelPrevention
Summary
This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2026-10-01
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Propranolol | Small molecule | 0.01 mg/kg | Intravenous |
| Subject | Propranolol | Small molecule | 0.02 mg/kg | Intravenous |
| Subject | Propranolol | Small molecule | 0.03 mg/kg | Intravenous |
| Subject | Propranolol | Small molecule | 0.04 mg/kg | Intravenous |
| Subject | Propranolol | Small molecule | 0.05 mg/kg | Intravenous |